NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Hoffmann-La Roche
Conditions: Non-Hodgkin's Lymphoma
Interventions: Idasanutlin, Obinutuzumab, Rituximab
Countries: United States, Australia, Germany, New Zealand, South Korea
This is a open-label, multicenter, non-randomized, study to evaluate the safety, efficacy, and pharmacokinetics of idasanutlin in combination with obinutuzumab in participants with R/R FL and rituximab in combination with idasanutlin in R/R DLBCL. The study will include an initial dose-escalation phase followed by an expansion phase. The dose-escalation phase is designed to determine the recommended phase 2 dose (RP2D) for idasanutlin in combination with obinutuzumab for FL and in combination with rituximab for DLBCL. The expansion phase is designed to further assess the safety and efficacy of obinutuzumab in combination with idasanutlin at the RP2D with the selected regimen in participants with R/R FL and of rituximab in combination with idasanutlin at the RP2D in participants with R/R DLBCL.
Sex: ALL
Age: 18 Years to —
Healthy volunteers: No
Study type: INTERVENTIONAL
Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 * Histologically documented cluster of differentiation (CD) 20-positive B-cell lymphoma classified as relapsed or refractory FL or DLBCL after treatment with at least two prior chemoimmunotherapy regimens that included an anti-CD20 monoclonal antibody (mAb) and for which no other more appropriate treatment option exists * At least one bidimensionally measurable lesion * Agreement to remain abstinent or use adequate contraception, among women or men of childbearing potential Exclusion Criteria: * Known CD20-negative status at relapse or progression * Prior allogeneic stem cell transplantation (SCT), or autologous SCT within 100 days prior to Day 1 of Cycle 1 * Current use of systemic corticosteroids greater than (\>) 20 mg prednisone per day (or equivalent), or prior anti-cancer therapy to include: radioimmunoconjugate within 12 weeks; mAb or antibody-drug conjugate within 4 weeks; or radiotherapy/chemotherapy/hormone therapy/targeted small-molecule therapy within 2 weeks prior to Day 1 of Cycle 1 * Requirement for chronic anticoagulation * Central nervous system (CNS) disease * Active infection * Positive for human immunodeficiency virus (HIV) or hepatitis B or C * Receipt of a live virus vaccine within 28 days prior to Day 1 of Cycle 1 * Poor hematologic, renal, or hepatic function * Pregnant or lactating women * History of progressive multifocal leukoencephalopathy (PML)
- Phoenix, Arizona, United States
- Aurora, Colorado, United States
- Louisville, Kentucky, United States
- Cary, North Carolina, United States
- Pittsburgh, Pennsylvania, United States
- Sayre, Pennsylvania, United States
- Providence, Rhode Island, United States
- Richmond, Virginia, United States
- Randwick, New South Wales, Australia
- Westmead, New South Wales, Australia
- Nedlands, Western Australia, Australia
- Augsburg, Germany
- Berlin, Germany
- Cologne, Germany
- Heilbronn, Germany
- Würzburg, Germany
- Auckland, New Zealand
- Christchurch, New Zealand
- Grafton, New Zealand
- Daegu, South Korea
- Gyeonggi-do, South Korea
- Seoul, South Korea
- Seoul, South Korea
- Seoul, South Korea